As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs. That fiction is now becoming a reality with cell therapies from companies like Juno (curing two infants with leukemia of their previously treatment resistant cancers with engineered T-cells), induced pluripotent stem cells (iPS) pioneered by the Nobel prize winning scientist, Shinya Yamanaka that can become any cell in the body, growing organoids (mini organs with some function of a fully grown organ like the stomach organoids grown by researchers in Ohio), and entirely re-grown organs. There are a plethora of biotechs focused on developing the next generation of regenerative therapies.

Ubisoft Senior Producer Mathieu Ferland demonstrates Dig Rush, created by Ubisoft and Amblyotech to be the first therapeutic video game used for the treatment of'lazy eye.' (Photo: Josh Edelson/AFP/Getty Images) "Make sure you play your video game," is not something you commonly hear parents say to kids. But Amblyotech's Amblyopad device armed with Ubisoft's video games Dig Rush and Monster Burner may change this...at least in some households. Amblyotech just filed for U.S. Food and Drug Administration (FDA) approval for these games to help treat "lazy eye," which is the lazier way of saying amblyopia. Amblyopia is when the one of your eye's vision is reduced because, as the National Eye Institute (NEI) describes, "the eye and the brain are not working together properly." In this condition which affects 3% of children, your brain favors using one eye over the other (assuming that you only have two eyes), perhaps because your eyes are misaligned (also called strabismus) or the vision in one eye is impaired.

Imaging and understanding the brain is getting so good we are on the cusp of truly enhancing it. This article originally appeared on SOSV.) As I start to look at the emerging trends of 2017 from the vantage of IndieBio, where we see hundreds of biotech startup applications and technologies per year, a few key themes are already emerging. Even as political landscapes change, science and technology continue to push forward. Most of us have seen science fiction shows that show future doctors regrowing and replacing entire organs.

In mobile marketplaces like the Apple App Store or the Google Play Store, there are thousands of apps that help track or care for personal health. And by and large, consumers have been big fans of these apps. According to an estimate from the Food and Drug Administration (FDA), more than 500 million smartphone users are actively using a health care-related application. And, according to the FDA's projections, more than 1.5 billion smartphone users will have downloaded a mobile health app by 2018. While these apps may enable users to take better care of their personal health, because they are designed for use by a mass audience, they often lack the personalization and one-on-one experience that health care typically requires.

Artificial Intelligence already had a massive impact in the past years, but where will AI be in the coming years? Here is a list of predictions. Waiting to make their moveAsia's looming labour shortage p There is an obvious solution p print-edition iconFrom the print edition Asia p Feb 11th 2017 p THE … The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI and machine learning in healthcare and industry as a whole. Until recently, artificial intelligence (AI) was similar to nuclear fusion in unfulfilled promise. ManpowerGroup, one of the world's largest jobs companies, released a report detailing how the technological revolution is going to change the … Replacing the real world with a virtual one is a neat trick.

A new fertility technique allows doctors to replace defective DNA found within a mother's egg with the DNA from another female donor. The result is a baby born with the DNA of two mothers. The first three-parent baby may potentially be born around Christmas of 2017. A new fertility technique allows doctors to replace defective DNA found within a mother's egg with the DNA Scientists will discover the truth behind "dark matter" Dark matter, a mysterious type of matter that makes up a little more than a quarter of the universe, is several experiments away from being detected. Dr. Katherine Freese, an expert in the field of dark matter, says 2017 may be the year "the 80-year-old dark matter puzzle will finally be solved."

So. You're single, it's the weekend, and you don't want a rerun of last Saturday night's chocolate chip pancakes a la mode and Gilmore Girls bingefest. Is it too early to fire up Tinder? In the age of the app, you never have to be alone if you don't want to be. And to make sure you don't get more than you bargained for from your hook-up, a number of companies are now offering a way to share STD test results through your phone. In the last few years, services like myLAB Box, Mately, and GetTested have cropped up to meet millennials where they like to meet sexual partners--online.

India's patent laws allow for reverse-engineering of certain technologies. A prime example of this reverse-engineering is in the pharmaceutical space, where Indian pharma companies are allowed to reverse-engineer drugs, especially life-saving ones. These drugs may have been developed by pharma majors in other parts of the world--and then introduced into western markets--after India-based outsourcing firms had helped them out with clinical trials, data gathering and reporting to the US Food and Drug Administration (FDA) or its equivalent to get these drugs passed. Indian courts have continued to allow such reverse-engineering of drugs--famously prompting Bayer AG's then CEO Martin Dekkers to say at a conference a few years ago, "We did not develop this medicine for Indians. We developed it for western patients who can afford it."

An insider's guide to the business and future of connected technology". Then on BioTech Nation, how much do we know about the clinical trials behind drugs approved by the FDA? JENNIFER MILLER, the Founder and President of Bioethics, International and a professor at NYU Medical School, talks about the Good Pharma Scorecard.

If you ask 100 people for the definition of "artificial intelligence," you'll get at least 100 answers, if not more. At AWS, we define it as a service or system which can perform tasks that usually require human-level intelligence such as visual perception, speech recognition, decision making, or translation. On this new AWS blog, we'll be covering these areas and more, with in-depth technical content, customer stories, and new feature announcements. The challenges related to building sophisticated AI systems center mostly around scale: the datasets are large, training is computationally hungry, and inferring predictions can be challenging to do at scale or on lower-power and mobile devices. Customers have been using AWS to solve these general problems for years, and the ability to be able to access storage, GPUs, CPUs, and IoT services on demand has emerged as a perfect fit for intelligent systems in production.